The U.S. Food and Drug Administration has authorized another at-home test kit for cervical cancer screening, giving patients a second option to collect their own HPV samples without visiting a clinic. The Onclarity HPV assay from Waters Corporation received FDA clearance this week, marking a shift toward broader access to early detection tools that could save lives by catching precancerous changes sooner.

The Teal Wand, developed by Teal Health, remains the only other FDA-approved HPV self-collection device currently available with a prescription. Both kits allow people to collect vaginal samples at home and mail them to a lab for analysis, reducing travel time and clinic wait times that often delay screenings for millions of women each year. Public health officials say these innovations address persistent access gaps, particularly in rural and underserved communities where routine Pap smears are harder to obtain.

Cervical cancer is nearly always caused by persistent infection with human papillomavirus (HPV), the most common sexually transmitted infection in the U.S. The Centers for Disease Control and Prevention estimates that HPV causes more than 90 percent of cervical cancer cases, which remains one of the most preventable cancers when caught early through regular screening. Despite proven screening methods, about 13,000 women in the U.S. are diagnosed with cervical cancer annually, and roughly 4,000 die from the disease each year.

How at-home HPV tests work

At-home HPV self-collection kits like Onclarity and Teal Wand use a simple swab or wand inserted into the vagina to collect cells. The sample is then sealed and sent to a lab for HPV DNA testing. Results typically return within days and are reviewed by a healthcare provider. Positive results may prompt a follow-up visit for a colposcopy or biopsy, while negative results may extend screening intervals for those at average risk.

Experts say convenience and privacy are major benefits of self-collection. Many women avoid screenings due to discomfort, time constraints, or stigma associated with pelvic exams. A 2023 study in the Journal of Clinical Oncology found that offering at-home HPV tests increased screening participation by up to 30 percent among underscreened populations. The kits could play a key role in meeting the American Cancer Society goal of eliminating cervical cancer as a public health problem in the U.S. by 2040.

Cost and insurance coverage remain barriers

While the FDA’s clearance paves the way for wider use, cost and insurance reimbursement still vary widely. The Onclarity kit is expected to launch commercially in the next few months, with pricing details to be announced. The Teal Wand, available by prescription, is covered by some insurance plans, including Medicare in certain states, but out-of-pocket costs can still reach hundreds of dollars for uninsured patients. Advocates are pushing for broader coverage under the Affordable Care Act to ensure equitable access.

Health systems and policymakers are also studying how to integrate self-collection into existing screening programs. The American College of Obstetricians and Gynecologists has endorsed at-home HPV testing as a safe and effective alternative to clinic-based exams, especially for those with limited access to care. Some states have begun pilot programs to distribute free or low-cost kits through community health centers and pharmacies.

Experts caution that while self-collection kits are a step forward, they are not a replacement for comprehensive reproductive health care. Regular screenings should still be paired with HPV vaccination for adolescents and young adults to maximize prevention. The FDA’s decision reflects a growing recognition that innovation in screening tools must match advances in treatment to reduce cancer disparities nationwide.

As demand grows, manufacturers are expected to refine designs and expand availability. For now, patients interested in at-home HPV testing should consult their healthcare provider to determine eligibility and confirm insurance coverage.

What You Need to Know

  • Source: Healthline
  • Published: May 16, 2026 at 21:04 UTC
  • Category: Health
  • Topics: #health · #wellness · #medicine · #cancer · #another · #home-cervical-cancer

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on Healthline →

All reporting rights belong to the respective author(s) at Healthline. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O Brasil pode ganhar em breve mais uma ferramenta poderosa no combate ao câncer de colo de útero, doença que ainda mata milhares de mulheres todos os anos no país. A aprovação recente pela FDA, agência reguladora americana, de um novo teste caseiro de detecção do HPV — causa principal da doença — acende a esperança de que métodos mais acessíveis cheguem também ao Sistema Único de Saúde (SUS). Com a inovação, especialistas brasileiros já discutem como adaptar essa tecnologia para ampliar o rastreamento, especialmente em regiões onde o acesso a exames preventivos ainda é limitado.

O contexto brasileiro é urgente: o câncer de colo de útero é o terceiro tumor mais comum entre mulheres no país, segundo o INCA, e a taxa de mortalidade segue alta, em parte pela baixa adesão aos exames de rotina, como o Papanicolau. O novo teste, que já está disponível nos EUA, permite que as mulheres coletem a amostra em casa e a enviem para análise laboratorial, dispensando consultas presenciais e reduzindo barreiras como distância, vergonha ou falta de tempo. Para o Brasil, onde a desigualdade no acesso à saúde persiste, essa abordagem poderia ser um divisor de águas, aproximando a prevenção de milhões de mulheres, especialmente nas periferias e no interior do país.

Agora, a expectativa é que a Anvisa avalie a liberação do produto no Brasil, enquanto o Ministério da Saúde estuda estratégias para incorporá-lo ao SUS sem onerar o sistema. Se aprovado, o teste caseiro poderia se tornar mais um aliado na meta de eliminar a doença como problema de saúde pública até 2030, como preconiza a Organização Mundial da Saúde.

🇪🇸 Resumen en Español

La Administración de Alimentos y Medicamentos de EE.UU. (FDA) ha dado luz verde a un nuevo test de detección del virus del papiloma humano (VPH) para realizar en casa, una herramienta que promete revolucionar el acceso a la prevención del cáncer de cuello uterino.

Este avance llega en un momento en el que la detección temprana sigue siendo clave para reducir la mortalidad por esta enfermedad, especialmente en regiones con barreras geográficas o económicas para los chequeos ginecológicos. Los expertos destacan que, al facilitar las pruebas en el ámbito doméstico, se podrían acortar los retrasos en los diagnósticos y salvar vidas, aunque advierten sobre la necesidad de garantizar un seguimiento médico adecuado. Para las mujeres hispanohablantes, tanto en EE.UU. como en Latinoamérica —donde el cáncer de cuello uterino sigue siendo una de las principales causas de muerte por cáncer—, esta innovación podría significar un paso crucial hacia una mayor equidad en salud.